155 related articles for article (PubMed ID: 16193576)
1. A lame duck, a dark horse, and a goat.
Huff B
GMHC Treat Issues; 2005; 19(5-6):4-5. PubMed ID: 16193576
[No Abstract] [Full Text] [Related]
2. When and how to use tipranavir and darunavir.
Hoffman CJ; Gallant JE
AIDS Read; 2007 Apr; 17(4):194-8, 201. PubMed ID: 17479503
[No Abstract] [Full Text] [Related]
3. Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.
AIDS Patient Care STDS; 2007 Aug; 21(8):6-3. PubMed ID: 17902242
[No Abstract] [Full Text] [Related]
4. FDA approves tipranavir.
IAPAC Mon; 2005 Jul; 11(7):190. PubMed ID: 16676422
[No Abstract] [Full Text] [Related]
5. New drugs.
Waters L; Nelson MR
HIV Med; 2005 Jul; 6(4):225-31. PubMed ID: 16011526
[No Abstract] [Full Text] [Related]
6. FDA approval: tipranavir.
Sax PE
AIDS Clin Care; 2005 Aug; 17(8):78. PubMed ID: 16193574
[No Abstract] [Full Text] [Related]
7. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
Hughes A; Barber T; Nelson M
J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
[TBL] [Abstract][Full Text] [Related]
8. FDA notifications. Tentative approval to Aptivus for combination ART.
AIDS Alert; 2007 Dec; 22(12):144. PubMed ID: 18411486
[No Abstract] [Full Text] [Related]
9. Salvage therapy update.
Emery C
Surviv News (Atlanta Ga); 2005; 16(6):8. PubMed ID: 16388538
[No Abstract] [Full Text] [Related]
10. New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
Lascar M; Cartledge JD
J HIV Ther; 2008 Jun; 13(2):40-4. PubMed ID: 18953273
[No Abstract] [Full Text] [Related]
11. FDA notifications. Accelerated approval of tipranavir.
AIDS Alert; 2005 Nov; 20(11):131. PubMed ID: 16363051
[No Abstract] [Full Text] [Related]
12. Protease inhibitors: the current status.
Dauer B
J HIV Ther; 2005 Dec; 10(4):72-4. PubMed ID: 16519246
[No Abstract] [Full Text] [Related]
13. Tipranavir (Aptivus): approval cautiously recommended.
James JS
AIDS Treat News; 2005 May; (412):2-3. PubMed ID: 16047408
[TBL] [Abstract][Full Text] [Related]
14. Tipranavir gets approved.
AIDS Patient Care STDS; 2005 Sep; 19(9):615-6. PubMed ID: 16245408
[No Abstract] [Full Text] [Related]
15. FDA approves Aptivus (tipranavir).
Pham PA
Hopkins HIV Rep; 2005 Jul; 17(4):6-7. PubMed ID: 16419308
[No Abstract] [Full Text] [Related]
16. Relative antiviral efficacy should not be inferred from cross-trial comparisons.
Hall D
HIV Med; 2007 Nov; 8(8):570-1; author reply 571-2. PubMed ID: 17944692
[No Abstract] [Full Text] [Related]
17. Aptivus in the hotseat. Excerpts from the FDA hearings.
Huff B
GMHC Treat Issues; 2005; 19(5-6):6-8. PubMed ID: 16193577
[No Abstract] [Full Text] [Related]
18. [Desensitization to tipranavir caused by toxicodermia].
Martínez Castro B; Ferrando Piqueres R; Martínez García M; Soler Company E
Farm Hosp; 2009; 33(6):340-2. PubMed ID: 20038397
[No Abstract] [Full Text] [Related]
19. Aptivus capsules granted full FDA approval.
AIDS Patient Care STDS; 2007 Nov; 21(11):889-90. PubMed ID: 18338430
[No Abstract] [Full Text] [Related]
20. HIV drug now approved for use with protease inhibitors.
Nurse Pract; 1998 Oct; 23(10):89. PubMed ID: 9805335
[No Abstract] [Full Text] [Related]
[Next] [New Search]
